ScripMerus’ petosemtamab is now tipped to be a future standard of care in PD-L1 positive head and neck cancer after updated Phase II results showed that it clearly improved response rates and overall survi
In VivoWhen Hans Clevers took the helm of Pharma Research and Early Development (pRED) at Roche, he faced a unique challenge: scaling the leadership principles he had developed running a 35-person academic l
ScripScrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. B+L Bolsters Ophthalmology With Acquis
ScripScrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Zhifei Commits To Acquiring $2.93bn Of